A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A

Spencer, Kevin; Souter, Vivienne; Tul, Natasha; J. M. Snijders, R.; H. Nicolaides, K.

doi:10.1046/j.1469-0705.1999.13040231.x

Public

A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A

Published in Ultrasound in Obstetrics and Gynecology • Apr 1, 1999

Authors:

Kevin Spencer

Vivienne Souter

Natasha Tul

Abstract

OBJECTIVE: To examine the potential impact of combining maternal age with fetal nuchal translucency thickness and maternal serum free beta-human chorionic gonadotropin (beta-hCG) and pregnancy-associated plasma protein-A (PAPP-A) in screening for trisomy 21 at 10-14 weeks of gestation. METHODS: Mate...

Subject

Trisomy

Pregnancy-associated plasma protein A

Obstetrics

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!